MICHAEL STEWART: Open Payments
NPI 1154604205 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,429 in 105 payments from 14 companies in 2025. Trend: 2023 $1,287 · 2024 $952 · 2025 $3,429
Food & beverage: $3,429
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $707 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $539 |
| Alkermes, Inc. | 13 | $408 |
| Indivior Inc. | 12 | $330 |
| E.R. Squibb & Sons, L.L.C. | 11 | $281 |
| Janssen Pharmaceuticals, Inc | 8 | $264 |
| Neurocrine BioSciences, Inc. | 9 | $261 |
| Lundbeck LLC | 5 | $190 |
| Teva Pharmaceuticals USA, Inc. | 4 | $159 |
| Braeburn Inc. | 1 | $125 |
Products named: REXULTI, CAPLYTA, SUBLOCADE, COBENFY, ARISTADA, INVEGA SUSTENNA, INGREZZA, ABILIFY MAINTENA.
Industry payments across MI — which companies pay providers there.
